Status:
COMPLETED
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel
Lead Sponsor:
Seoul National University Hospital
Conditions:
Acute Coronary Syndrome
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Brief Summary
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top...
Eligibility Criteria
Inclusion
- Patients who were diagnosed with acute coronary syndrome and underwent percutaneous coronary intervention
Exclusion
- Patients administered with glycoprotein IIb/IIIa inhibitiors
- Patients with atrial fibrillation
- Patients with high risk of bleeding at the physician's discretion
- Patients with renal impairment (estimated GFR \<30ml/min)
Key Trial Info
Start Date :
April 12 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 4 2018
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03481257
Start Date
April 12 2017
End Date
February 4 2018
Last Update
March 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463707